BRPI0810717A2 - sulfonato hidroxi de composto de quinona e seus usos - Google Patents

sulfonato hidroxi de composto de quinona e seus usos

Info

Publication number: BRPI0810717A2
Authority: BR; Brazil
Prior art keywords: quinone compound; hydroxy sulfonate; sulfonate; hydroxy; quinone
Prior art date: 2007-04-30

Application number

BRPI0810717A

Other languages

English (en)

Inventor

Deirdre Lowe

Erika Volckova

Judit Bartis

Manish Tandon

Marty Redmon

Original Assignee

Arqule Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-30

Filing date

2008-04-30

Publication date

2016-05-24

2008-04-30 Application filed by Arqule Inc filed Critical Arqule Inc

2016-05-24 Publication of BRPI0810717A2 publication Critical patent/BRPI0810717A2/pt

Links

QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 title 1
-1 quinone compound Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pyrane Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0810717A 2007-04-30 2008-04-30 sulfonato hidroxi de composto de quinona e seus usos BRPI0810717A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91497107P	2007-04-30	2007-04-30
PCT/US2008/005656 WO2008134088A1 (en)	2007-04-30	2008-04-30	Hydroxy sulfonate of quinone compounds and their uses

Publications (1)

Publication Number	Publication Date
BRPI0810717A2 true BRPI0810717A2 (pt)	2016-05-24

Family

ID=39494644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810717A BRPI0810717A2 (pt)	2007-04-30	2008-04-30	sulfonato hidroxi de composto de quinona e seus usos

Country Status (13)

Country	Link
US (1)	US7790765B2 (pt)
EP (1)	EP2152686B1 (pt)
JP (1)	JP2010526072A (pt)
KR (1)	KR20100017483A (pt)
CN (1)	CN101687835B (pt)
AU (1)	AU2008246067B2 (pt)
BR (1)	BRPI0810717A2 (pt)
CA (1)	CA2685739C (pt)
DK (1)	DK2152686T3 (pt)
ES (1)	ES2532656T3 (pt)
MX (1)	MX2009011822A (pt)
TW (1)	TWI401081B (pt)
WO (1)	WO2008134088A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100209513A1 (en) *	2007-10-11	2010-08-19	In Geun Jo	Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
KR101405823B1 (ko) *	2007-12-24	2014-06-12	주식회사 케이티앤지생명과학	녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) *	2007-12-28	2009-07-02	주식회사 머젠스	신장질환의 치료 및 예방을 위한 약제 조성물
ES2694582T3 (es) *	2011-01-31	2018-12-21	Lucolas-M.D. Ltd.	Combinaciones de inhibidores de aromatasa y antioxidantes
US9343930B2 (en) *	2012-05-25	2016-05-17	Baldor Electric Company	Segmented stator assembly
BR112017000319B1 (pt) *	2014-07-10	2022-06-28	Robert Bosch Gmbh	Módulo de motor e unidade hidráulica abs
WO2016200934A1 (en) *	2015-06-08	2016-12-15	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Mitochondria-targeted lapachone compounds and uses therefor
US11090389B2 (en)	2016-10-13	2021-08-17	University of Pittsburgh—of the Commonwealth System of Higher Education	Mitochondrially targeted PARP inhibitor, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0040506B1 (en)	1980-05-21	1986-08-20	Teijin Limited	Reactive polymer and process for the preparation thereof
US4963565A (en) *	1986-07-30	1990-10-16	National Jewish Center For Immunology And Respiratory Medicine	In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone
US5120843A (en) *	1987-04-27	1992-06-09	Upjohn	Pharmaceutically active amines
FI102273B (fi) *	1989-09-11	1998-11-13	Eisai Co Ltd	Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
JP3111099B2 (ja)	1991-10-31	2000-11-20	科学技術振興事業団	水溶性高分子化薬剤の製造法
US5559156A (en) *	1993-09-30	1996-09-24	Glaxo Wellcome, Inc.	Method for treating animals infected with Babesia spp.
WO1994004145A1 (en)	1992-08-21	1994-03-03	Dana Farber Cancer Institute	Treatment of human viral infections
US5672607A (en) *	1993-01-29	1997-09-30	The United States Of America As Represented By The Department Of Health And Human Services	Antiviral naphthoquinone compounds, compositions and uses thereof
GB2282384B8 (en)	1993-08-18	1997-09-04	Europ Economic Community	Drug delivery agents incorporating mitomycin
EP0640609A1 (en) *	1993-08-24	1995-03-01	Ono Pharmaceutical Co., Ltd.	Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5880131A (en) *	1993-10-20	1999-03-09	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5840900A (en) *	1993-10-20	1998-11-24	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5763625A (en)	1995-04-25	1998-06-09	Wisconsin Alumni Research Foundation	Synthesis and use of β-lapachone analogs
US5674900A (en) *	1995-06-06	1997-10-07	Shaman Pharmaceuticals, Inc.	Terpenoid-type quinones for treatment of diabetes
US6245807B1 (en) *	1995-08-24	2001-06-12	Dana-Farber Cancer Institute	Treatment of human prostate disease
US5824700A (en) *	1996-02-20	1998-10-20	Wisconsin Alumni Research Foundation	Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
PL189698B1 (pl)	1996-03-12	2005-09-30	Pg Txl Co	Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
AU2411197A (en)	1996-04-30	1997-11-19	Affymax Technologies N.V.	Methods for the synthesis of fmoc protected amines
ES2273688T3 (es) *	1999-04-14	2007-05-16	Dana-Farber Cancer Institute, Inc.	Procedimiento y composicion para el tratamiento de cancer.
MXPA01011008A (es)	1999-04-30	2003-06-30	Slil Biomedical Corp	Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata.
US6376470B1 (en) *	1999-09-23	2002-04-23	Enzon, Inc.	Polymer conjugates of ara-C and ara-C derivatives
MXPA02003719A (es)	1999-10-12	2002-08-30	Cell Therapeutics Inc	Fabricacion de congujados de poliglutamato-agente terapeutico.
KR20020082888A (ko)	2000-03-17	2002-10-31	쎌세러퓨틱스,인코포레이티드	폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법
US20020169135A1 (en)	2000-11-07	2002-11-14	Pardee Arthur B.	Method of treating hematologic tumors and cancers
US6458974B1 (en) *	2001-01-25	2002-10-01	Cyclis Pharmaceuticals, Inc.	Synthesis of β-lapachone and its intermediates
US6962944B2 (en) *	2001-07-31	2005-11-08	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) *	2001-07-31	2006-07-11	Arqule, Inc.	Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CZ293787B6 (cs)	2001-12-20	2004-07-14	Zentiva, A.S.	pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
US6890950B2 (en)	2002-04-23	2005-05-10	Case Western Reserve University	Lapachone delivery systems, compositions and uses related thereto
US6608076B1 (en) *	2002-05-16	2003-08-19	Enzon, Inc.	Camptothecin derivatives and polymeric conjugates thereof
WO2004006849A2 (en)	2002-07-15	2004-01-22	Combinatorx, Incorporated	Combinations of drugs for the treatment of neoplasms
JP2006508147A (ja)	2002-11-18	2006-03-09	アルキュール，インコーポレイテッド	新規ラパコン化合物およびその使用方法
JP2007523191A (ja)	2004-02-20	2007-08-16	アークル・インコーポレーテツド	血液腫瘍の治療のためのβ−ラパコンの使用
CA2556823A1 (en)	2004-02-20	2005-09-09	Arqule, Inc.	Use of beta-lapachone for the treatment of lung cancer
WO2006020719A2 (en) *	2004-08-11	2006-02-23	Arqule, Inc.	Aminoacid conjugates of beta - lapachone for tumor targeting
US8614228B2 (en) *	2004-08-11	2013-12-24	Arqule, Inc.	Quinone prodrug compositions and methods of use
WO2006128120A2 (en)	2005-05-26	2006-11-30	Arqule, Inc.	Novel lapachone compounds and methods of use thereof

2008
- 2008-04-30 BR BRPI0810717A patent/BRPI0810717A2/pt not_active Application Discontinuation
- 2008-04-30 JP JP2010506326A patent/JP2010526072A/ja not_active Withdrawn
- 2008-04-30 US US12/150,914 patent/US7790765B2/en active Active
- 2008-04-30 MX MX2009011822A patent/MX2009011822A/es active IP Right Grant
- 2008-04-30 TW TW097115955A patent/TWI401081B/zh active
- 2008-04-30 EP EP08754188.4A patent/EP2152686B1/en active Active
- 2008-04-30 WO PCT/US2008/005656 patent/WO2008134088A1/en not_active Ceased
- 2008-04-30 KR KR1020097024913A patent/KR20100017483A/ko not_active Withdrawn
- 2008-04-30 CA CA2685739A patent/CA2685739C/en active Active
- 2008-04-30 DK DK08754188.4T patent/DK2152686T3/en active
- 2008-04-30 ES ES08754188.4T patent/ES2532656T3/es active Active
- 2008-04-30 AU AU2008246067A patent/AU2008246067B2/en active Active
- 2008-04-30 CN CN200880022708.XA patent/CN101687835B/zh active Active

Also Published As

Publication number	Publication date
AU2008246067A1 (en)	2008-11-06
US20090028952A1 (en)	2009-01-29
CA2685739A1 (en)	2008-11-06
TW200913986A (en)	2009-04-01
JP2010526072A (ja)	2010-07-29
KR20100017483A (ko)	2010-02-16
WO2008134088A1 (en)	2008-11-06
CN101687835B (zh)	2015-08-19
HK1139411A1 (en)	2010-09-17
DK2152686T3 (en)	2015-01-12
MX2009011822A (es)	2010-01-14
EP2152686B1 (en)	2014-12-17
US7790765B2 (en)	2010-09-07
AU2008246067B2 (en)	2011-10-20
EP2152686A1 (en)	2010-02-17
CA2685739C (en)	2016-06-14
TWI401081B (zh)	2013-07-11
CN101687835A (zh)	2010-03-31
ES2532656T3 (es)	2015-03-30

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-09	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-07-23	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
BRPI0909185A2 (pt)	2015-08-25	Derivado de vitamina e e seus usos
BRPI0908853A2 (pt)	2017-05-30	composto oligopeptídicos e seus usos
BRPI0813244A2 (pt)	2014-12-23	Compostos e seus usos 708
BRPI0913640A2 (pt)	2016-08-16	substâncias policrômicas e seus usos
BRPI0908268A2 (pt)	2018-10-30	compostos do inibidor de raf e seus métodos de uso
BRPI0921862A2 (pt)	2015-12-29	inibidores de raf e seus usos
BRPI0910746A2 (pt)	2016-07-26	reticuladores e seus usos
BRPI0817234A2 (pt)	2014-09-30	Análogos de azacitidina e seus usos
BRPI0817881A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
PT2473528E (pt)	2015-03-04	Formulações estáveis de polipéptidos e seus usos
BRPI1011384A2 (pt)	2016-03-15	pro-proteinas e seus metodos de uso
BRPI0809103A2 (pt)	2016-08-02	composições de magnésio e seus usos
BR112012000660A2 (pt)	2016-11-16	compostos heterociclos e seus usos
BRPI0710878A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
BRPI0906387A2 (pt)	2015-07-07	Anticorpos alfa 5 - beta 1 e seus usos
BRPI1005292A2 (pt)	2016-03-22	composição de decapagem e uso da composição
BRPI0906980A2 (pt)	2015-07-21	Composição de derivados e maleatados
BRPI0906498A2 (pt)	2015-07-14	Anticorpo ron e seus usos
BR112012018329A2 (pt)	2016-04-19	agentes de coloração e métodos de uso destes
BRPI0906518A2 (pt)	2015-07-14	Formas cristalinas do dimetóxi docetaxel e seus processos de preparação
CR10815A (es)	2009-08-12	Nuevos derivados de isoquinolina e isoquinolinona sustituidos
BRPI0916269A2 (pt)	2018-05-29	dispositivo de modificação de tecido e seu método de uso
BRPI0916769A2 (pt)	2017-09-26	derivados de benzilbenzeno deuterados e métodos de uso
BR112012004375A2 (pt)	2016-03-15	toalha de praia e método de toalha de praia
BRPI1010540A2 (pt)	2016-03-15	"anticorpos especéficos para dkk-1 e seus usos"